Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Equasens Société anonyme is a French société anonyme specializing in healthcare IT solutions across Europe. Founded in 1996, originally as Pharmagest Interactive, it develops and integrates professional software for healthcare professionals and establishments, including pharmacists, doctors, nurses, hospitals, nursing homes, retirement homes, and home care services. The company excels in interoperability solutions that enhance coordination among healthcare actors and facilitate secure patient data exchanges, positioning it as the leading publisher of healthcare software in terms of market share and business coverage. Key offerings encompass pharmacy management systems for stocks, orders, and electronic prescriptions (75.4% of revenue), software for sanitary and medico-social facilities like admissions and billing (14.8%), and e-health infrastructures including telemedicine and digital communication tools (9.8%). With operations in France, Italy, Germany, Spain, Portugal, Belgium, Luxembourg, Ireland, and the UK, Equasens supports the transformation of healthcare delivery through innovative, high-value-added services, employing around 1,400 people and headquartered in Villers-les-Nancy, France. Its role underscores the growing demand for digital integration in the healthcare sector.
Margins and capital returns are both well above average: 20.24% operating margin, ROIC at 21.05%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€237M
Net Income (TTM)
€41M
Op. Margin
20.24%
ROIC
21.05%
Cash Flow & Balance Sheet
FCF (TTM)
€47M
▲ +31.4% YoY
Op. Cash Flow (TTM)
€47M
▲ +31.4% YoY
Net Debt
-€26M
Net Cash Position
Cash & Equiv.
€87M
3Y CAGR: +7.0%
3Y CAGR: +0.3%
Continue Research